Efficacy and Adverse Effects of Memantine Treatment for Alzheimer's Disease from Randomized Controlled Trials

Overview

Journal Neurol Sci

Specialty Neurology

Date 2015 Apr 23

PMID 25899425

Citations 21

Authors

Jue Jiang

Hong Jiang

Affiliations

Soon will be listed here.

Abstract

The role of memantine as a treatment for Alzheimer's disease (AD) has been controversial. In clinical trials, a high dropout rate and numerous adverse events associated with memantine have been observed. However, given the relative scarcity of effective treatments for AD it would seem prudent to re-examine existing evidence to determine whether or not memantine should be used. Eight databases were utilized for randomized controlled trials that were published prior to December 31, 2013 and were according with the inclusion criteria. Trial methods, clinical characteristics, outcomes, and adverse events were extracted and analyzed with Review Manager 5.2. We obtained 2293 studies and determined that 13 of those studies met the inclusion criteria. Memantine therapy showed significant benefits to cognition, mental state, activities of daily life, the clinician's global impression in term with MMSE, SIB, NPI, ADCS-ADL19, CIBIC-Plus, respectively. Memantine therapy did not significantly increase the incidence of total adverse events, serious adverse events, death but it did increase the risk for somnolence.

Citing Articles

Evaluating Quinolines: Molecular Dynamics Approach to Assess Their Potential as Acetylcholinesterase Inhibitors for Alzheimer's Disease.

Prejano M, Romeo I, Felipe Hernandez-Ayala L, Gabriel Guzman-Lopez E, Alcaro S, Galano A Chemphyschem. 2024; 26(1):e202400653.

PMID: 39301943 PMC: 11747580. DOI: 10.1002/cphc.202400653.

Formulating treatment of major psychiatric disorders: algorithm targets the dominantly affected brain cell-types.

Fessel J Discov Ment Health. 2023; 3(1):3.

PMID: 37861813 PMC: 10501034. DOI: 10.1007/s44192-022-00029-8.

Mixed Medicinal Mushroom Mycelia Attenuates Alzheimer's Disease Pathologies In Vitro and In Vivo.

Jeong J, Hong G, Jeong Y, Lee N, Kim D, Park J Curr Issues Mol Biol. 2023; 45(8):6775-6789.

PMID: 37623247 PMC: 10453438. DOI: 10.3390/cimb45080428.

Alzheimer Disease and Related Cognitive Impairment in Older Adults: A Narrative Review of Screening, Prevention, and Management for Manual Therapy Providers.

Rogers C, Ayuso Jr J, Hackney M, Penza C J Chiropr Med. 2023; 22(2):148-156.

PMID: 37346234 PMC: 10280085. DOI: 10.1016/j.jcm.2023.03.001.

Natural Products as the Potential to Improve Alzheimer's and Parkinson's Disease.

Kim S, Lee J, Kim B, Yang G, Kim J Int J Mol Sci. 2023; 24(10).

PMID: 37240173 PMC: 10218422. DOI: 10.3390/ijms24108827.

References

van Dyck C, Tariot P, Meyers B, Resnick E . A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007; 21(2):136-43. DOI: 10.1097/WAD.0b013e318065c495. View

Lockhart I, Orme M, Mitchell S . The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and meta-analysis. Dement Geriatr Cogn Dis Extra. 2011; 1(1):212-27. PMC: 3199891. DOI: 10.1159/000330032. View

Ferri C, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M . Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366(9503):2112-7. PMC: 2850264. DOI: 10.1016/S0140-6736(05)67889-0. View

Burke D . ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. Ann Intern Med. 2012; 156(12):JC6-10. DOI: 10.7326/0003-4819-156-12-201206190-02010. View

Tariot P, Farlow M, Grossberg G, Graham S, McDonald S, Gergel I . Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291(3):317-24. DOI: 10.1001/jama.291.3.317. View

Herrmann N, Gauthier S, Boneva N, Lemming O . A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. Int Psychogeriatr. 2013; 25(6):919-27. DOI: 10.1017/S1041610213000239. View

Saxton J, Hofbauer R, Woodward M, Gilchrist N, Potocnik F, Hsu H . Memantine and functional communication in Alzheimer's disease: results of a 12-week, international, randomized clinical trial. J Alzheimers Dis. 2011; 28(1):109-18. DOI: 10.3233/JAD-2011-110947. View

Schmidt R, Ropele S, Pendl B, Ofner P, Enzinger C, Schmidt H . Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. J Neurol Neurosurg Psychiatry. 2008; 79(12):1312-7. PMC: 2582338. DOI: 10.1136/jnnp.2007.141648. View

Grossberg G, Manes F, Allegri R, Gutierrez-Robledo L, Gloger S, Xie L . The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs. 2013; 27(6):469-78. PMC: 3680656. DOI: 10.1007/s40263-013-0077-7. View

10.

Parsons C, Danysz W, Quack G . Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. Neuropharmacology. 1999; 38(6):735-67. DOI: 10.1016/s0028-3908(99)00019-2. View

11.

Porsteinsson A, Grossberg G, Mintzer J, Olin J . Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008; 5(1):83-9. DOI: 10.2174/156720508783884576. View

12.

Bakchine S, Loft H . Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2008; 13(1):97-107. DOI: 10.3233/jad-2008-13110. View

13.

Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius H . Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003; 348(14):1333-41. DOI: 10.1056/NEJMoa013128. View

14.

Doody R, Tariot P, Pfeiffer E, Olin J, Graham S . Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement. 2009; 3(1):7-17. DOI: 10.1016/j.jalz.2006.10.004. View

15.

Yang Z, Zhou X, Zhang Q . Effectiveness and safety of memantine treatment for Alzheimer's disease. J Alzheimers Dis. 2013; 36(3):445-58. DOI: 10.3233/JAD-130395. View

16.

Fox C, Crugel M, Maidment I, Auestad B, Coulton S, Treloar A . Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS One. 2012; 7(5):e35185. PMC: 3342281. DOI: 10.1371/journal.pone.0035185. View

17.

NEWELL D . Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol. 1992; 21(5):837-41. DOI: 10.1093/ije/21.5.837. View

18.

Peskind E, Potkin S, Pomara N, Ott B, Graham S, Olin J . Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006; 14(8):704-15. DOI: 10.1097/01.JGP.0000224350.82719.83. View

19.

Wang T, Huang Q, Reiman E, Chen K, Li X, Li G . Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial. J Clin Psychopharmacol. 2013; 33(5):636-42. DOI: 10.1097/JCP.0b013e31829a876a. View

20.

Wilkinson D, Fox N, Barkhof F, Phul R, Lemming O, Scheltens P . Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. J Alzheimers Dis. 2012; 29(2):459-69. DOI: 10.3233/JAD-2011-111616. View